Stockreport

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data [Yahoo! Finance]

Pyxis Oncology, Inc.  (PYXS) 
PDF patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25 — Overall, 26% ORR across all six Solid Tumor Types of Inte [Read more]